Juvaris Products
Juvaris' proprietary technology platform is broad-based with wide ranging human and veterinary applications in the treatment and prevention of cancers as well as bacterial, viral, fungal and parasitic infections. The following is a summary of the major markets with significant unmet clinical needs where Juvaris technologies are believed applicable:

1. Vaccines for the Treatment and Prevention of Cancers.
Each year there are 711,000 new cases of the five leading cancers in the United States: prostate (198,100), breast (193,700), lung (169,500), colon (98,200) and melanoma (51,500). The annual cost of treatment of prostate cancer alone is over $1.2 billion. Many new cancer therapeutics are being developed, typically with annual revenue potential of $100 to $200 million within the first few years of introduction.

Utilizing the Juvaris technology to develop therapeutic vaccines for the most prevalent cancers listed above could produce five successful products, with revenues of $500 million to $1 billion. Juvaris intends to aggressively pursue partnerships to develop market opportunities in these areas.

2. Immunotherapeuti cs Against Bacterial, Viral, Fungal, and Parasitic Infections.

A. Bacterial:
Juvaris' technology can be utilized to develop effective immunotherapeutics against antibiotic-resistant bacteria that are increasingly life threatening. Acute and chronic infections, particularly those caused by antibiotic-resistant strains of staphylococcus, streptococci and enterococci, provide a large market opportunity for effective new treatments. Chronic bacterial pneumonia, tuberculosis, Pseudomonas, and pneumocistis also present market opportunities that Juvaris may pursue.

The worldwide market for anti-infective pharmaceuticals was $68 billion in 2001 and is growing at 8% per year. More specifically, there are approximately two million cases of hospital-acquired nosocomial infections with antibiotic-resistant organisms each year.

Because proof of efficacy for acute infections requires shorter clinical trials than for many diseases, the time required to bring anti-infectious agents to the market can be considerably shorter than for chronic diseases. The introduction of three or more Juvaris therapeutics against bacterial infections could produce revenues of $300 to $600 million within a few years of product registration. Juvaris intends to implement an internal R & D program to develop products for the anti-infective market. Management believes that the Juvaris technology, when fully developed, will provide unique product offerings in the anti-infectives marketplace.

B. Viral:
Infections caused by Herpes and human immunodeficiency virus (HIV) are currently treated with products with annual sales of $600 million for Herpes and $5 billion for HIV, respectively, providing a market opportunity for Juvaris immunotherapeutics. These projects will be supported by grants and/or co-development agreements.

C. Fungal/Parasitic:
Infections caused by this group of pathogens provide another market opportunity for Juvaris' therapeutic products, particularly for Malaria, a worldwide parasitic disease causing 300-500 million clinical cases each year. Juvaris is currently evaluating market opportunities in this area. These projects will be supported via grants or co-development agreements.

3. BioDefense:
Juvaris currently has proposals to a number of government agencies to test JuvImmune and JuvaVax in a wide variety of biowarfare animal models.

4. Veterinary Market:
The development of animal immunotherapeutic treatments represents a substantial market opportunity with annual revenues of $3 billion for companion-animal products, growing at a rate of 10% per year. Major pharmaceutical companies selling therapeutic products to the veterinary market include Pfizer ($254 million per year), Novartis ($1.083 billion) and Heska ($45 million). However, there are few effective treatments for many of the cancers and infectious diseases afflicting household pets, including virally caused feline leukemia. Juvaris founders have demonstrated initial efficacy using Juvaris technology to treat large-animal spontaneous tumors. One example of such an application is the use of JuvImmune in livestock to prevent a wide variety of respiratory diseases commonly referred to as shipping fever.